ValuEngine lowered shares of Avenue Therapeutics (NASDAQ:ATXI) from a hold rating to a sell rating in a research note published on Thursday morning.
Shares of ATXI opened at $4.79 on Thursday. Avenue Therapeutics has a 12 month low of $3.40 and a 12 month high of $8.58. The firm has a market cap of $49.02 and a PE ratio of -2.71.
Avenue Therapeutics (NASDAQ:ATXI) last issued its quarterly earnings data on Thursday, March 1st. The company reported ($0.63) EPS for the quarter. sell-side analysts expect that Avenue Therapeutics will post -2.74 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.thelincolnianonline.com/2018/04/15/avenue-therapeutics-atxi-cut-to-sell-at-valuengine.html.
About Avenue Therapeutics
Avenue Therapeutics, Inc is a pharmaceutical company. The Company is engaged in acquiring, licensing, developing and commercializing products principally for use in the acute or intensive care hospital setting. Its product candidate is intravenous (IV) Tramadol, an intravenous formulation of tramadol hydrochloride (HCl), for the management of moderate to moderately severe postoperative pain.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.